Genetic variation in the peptide-binding groove of the highly polymorphic human Main Text: 42 HLA class I proteins are thought to play a critical role in immune recognition of HIV-1 43 by presenting endogenously processed viral peptides at the surface of infected cells to 44 cytotoxic T cells, in order to trigger destruction of the infected cells 1 . Indeed, genetic 45 variation in the HLA region has repeatedly been identified as the major genetic 46 determinant of HIV-1 control in genome-wide association studies 2,3 . Most recently, 47
leukocyte antigen (HLA) class I molecules has repeatedly been associated with HIV-1 26 control and progression to AIDS, accounting for up to 12% of the variation in HIV-1 set 27 point viral load (spVL). This suggests a key role in disease control for HLA presentation 28 of HIV-1 epitopes to cytotoxic T cells. However, a comprehensive understanding of the 29 relevant HLA-bound HIV epitopes is still elusive. Here we developed a peptidome-wide 30 association study (PepWAS) approach that integrates HLA genotypes and spVL data 31 from 6,311 HIV-infected patients to interrogate the entire HIV-1 proteome (3,252 unique 32 peptides) for disease-relevant peptides. This PepWAS approach revealed a core set of 33 epitopes associated with spVL, including previously characterized epitopes but also 34 several novel disease-relevant peptides. More importantly, each patient presents only 16 35 (±7) and 6 (±6) of these core epitopes through their individual HLA-B and HLA-A 36 variants, respectively. Differences in these patient-specific epitope repertoires account for 37 almost all the variation in spVL previously associated with HLA genetic variation. 38
PepWAS thus enables a comprehensive functional interpretation of the robust but little 39 understood association between HLA and HIV-1 control, prioritizing a short and 40 targetable list of disease-associated epitopes for personalized immunotherapy. 41
McLaren et al. 4 fine-mapped the entire HLA's association with HIV-1 control and 48 disease progression to five independent amino acid residues in the peptide binding groove 49 of the HLA-B and HLA-A molecules. These five residues alone accounted for 12.3% of 50 the variation in viral load, suggesting a major role for specific HLA-presented viral 51 epitopes in HIV-1 control. However, our understanding of the disease-relevant viral 52 epitopes is still incomplete, hampered by the unfeasible challenge of employing a full-53
factorial experimental assay to screen the entirety of the HIV-1 peptidome for binding by 54 all relevant HLA alleles. Therefore, we developed a novel computational approach that 55 identifies and prioritizes disease-associated peptides based on individual HLA genotype 56 and disease phenotype information. Using a unique dataset of 6,311 individuals of 57
European ancestry with chronic HIV-1 infection (Table S1) HLA genotypes (4-digit allele resolution). We focused on the two HLA loci (HLA-B and 62 HLA-A) reported to have independent associations with HIV-1 control and disease 63 progression 4 . Potential HLA-bound peptides were identified using an established 64 computational algorithm that is based on empirical training data 6 and integrates several 65 complementary prediction methods in a consensus approach, outperforming comparable 66 algorithms 6,7 . Such algorithms have been used in a wide spectrum of HLA-related 67 studies ranging from vaccine design to cancer evolution and HIV disease genetics [8] [9] [10] . 68
Without a-priori selection, we screened all possible 9mer HIV-1 peptides (N = 3,252) in 69 a sliding window across the entire HIV-1 M group subtype B reference proteome 11 70 against all represented HLA-B and HLA-A alleles (344,712 HLA:peptide complexes), 71
In order to evaluate the significance of the predicted epitope repertoires, we interrogated 74 several layers of empirical evidence. Firstly, the identified subsets of predicted HLA-B-75 and HLA-A-bound HIV-1 peptides were strongly enriched for experimentally tested 76
cytotoxic T-lymphocyte (CTL) epitopes from the Los Alamos HIV Molecular 77
Immunology Database 12 (HLA-B: OR = 5.8, P < 0.0001; HLA-A: OR = 5.0, P < 0.0001; 78 Figure 1A ; Table S1 and S2). Several predicted HLA-peptide complexes, e.g. B*57:01-79 IW9 15-23 , B*58:01-SW9 241-249 , in Gag, B*14:01-EL9 584-592 in Env and B*57:01-HW9 116-80 124 , B*35:01-YY9 135-143 in Nef were previously shown to be either frequently recognized 81 by CD8 + T-cells 13 or associated with low viremia and slow disease progression 14, 15 . 82
Secondly, we observed a negative correlation between an allele's effect on spVL and the 83 number of HIV-1 peptides that are predicted to be bound by that allele (Kendall's tau = -84 0.26, P = 0.002; Figure 1B ; Table S3 ). This observation supports the assumption that a 85 greater number of HLA-presented peptides, together with the availability of a 86 corresponding diverse TCR repertoire, confer greater protection against HIV 10 . More 87 importantly, this correlation indicates that our computationally predicted peptides are 88 enriched for epitopes that contribute to the well-established association between HLA and 89 viral load. No such association was observed when correlating the HIV-specific allele 90 effect with binding to peptides from other viruses, confirming an HIV-1 peptide-specific 91 effect ( Figure S2 ). Thirdly, we used our prediction pipeline to identify HLA allele-92 specific escape variants in autologous HIV-1 sequences (available for a subset of 93 patients, Table 1 ). Escape variants exhibit sequence variation that impedes either HLA 94 binding or TCR binding to a given epitope and thus allow the virus to avoid CTL 95 recognition. Here we focused on variants escaping HLA binding, expected to evolve in 96 response to patient-specific HLA restriction [16] [17] [18] . Focusing on the allele HLA-B*57:01, 97 associated with strongest protection against HIV-1 16,19,20 , we tested whether autologous 98 sequences of patients carrying B*57:01 harbored more escape variants specific to this 99 allele than patients who did not carry this allele. Our autologous data covered 18 100 B*57:01-bound peptides, 12 of which showed no significant difference in the proportion 101 of escape variants between B*57:01 carriers and non-carriers. Of the six HIV-1 peptides 102 that did show a significant difference, all showed a higher proportion of escape variants 103 in B*57:01 carriers (Chi-squared test, all P < 0.01 after Bonferroni correction; Figure  104 suggests that our prediction pipeline identifies HLA-relevant variation in HIV-1 peptides. 106
Following these independent layers of evidence, we subsequently refer to these predicted 107 HLA-bound peptides as predicted epitopes. 108
Next, we tested whether the patient-specific repertoire of predicted HIV-1 epitopes, 109 defined by the number of peptides predicted to be bound by the specific HLA allele 110 combination of the patient, was associated with spVL. For this, we ran a linear regression 111 across the 6,315 HIV-1 patients. We first focused on known CTL epitopes from the Los 112
Alamos HIV Molecular Immunology Database 12 , of which 80 were represented among 113 the 214 predicted HLA-B bound epitopes. The total number of these known CTL 114 epitopes bound by patient-specific HLA-B variants accounted for only 1.8% variation in 115 spVL (Figure 2) . In contrast, the total number of all predicted HLA-B-bound epitopes 116 per patient (including known and 'uncharacterized' epitopes) accounted for 5.3% 117 variation in spVL (Figure 2 ). However, this was still lower than the 11.4% variation 118 associated with genetic variation at HLA-B in previous genotype-based studies, 119
suggesting that the total predicted epitope repertoire still included peptides irrelevant for 120 the association between HLA and HIV-1. We thus aimed to refine the repertoire of 121 predicted HLA-bound HIV-1 epitopes further to include only disease-relevant epitopes. 122
For this, we calculated the epitope-specific association with spVL by running a separate 123 linear regression for each predicted epitope and recording R 2 and β-coefficient as 124 measures of the epitope's effect on spVL. This is analogous to the approach of a genome-125 wide association study (GWAS), where each genetic variant is tested for its association 126 with a given trait, except that here we focus on functional protein variation (peptide 127 binding by a patient's HLA molecules) rather than genetic variation. Following this 128 analogy, we term our approach peptidome-wide association study (PepWAS). Of 214 129
HIV-1 epitopes predicted to be bound by HLA-B, 132 accounted for nominal variation 130 (adjusted R 2 value > 0) in spVL, 74 of which were negatively and 58 positively 131 associated with spVL (β-coefficients ranging from -0.1 to 0.77; Table S2 ). Importantly, 132
we do not require statistical significance at this point as this is a candidate screen and we 133 thus aim to minimize the number of false negatives. Subsequently, we designate the 134 nominally associated epitopes as disease-associated predicted epitopes, even though their 135 effects are not necessarily independent as they were tested with separate regression 136 additional 74 disease-associated epitopes (Table S3) . 138
Having refined the predicted HIV-1 epitope repertoire to only disease-associated 139 epitopes, we then tested whether this subset accounted for a larger fraction of the 140 variation in spVL than the total HIV-1 epitope repertoire. Indeed, the patients' ability to 141 bind a smaller or larger fraction of the HLA-B-specific disease-associated epitopes 142 independent genetic associations in the entire HLA (Figure 2A) . 154
Interestingly, Env protein showed the largest number of disease-associated predicted 155 epitopes, with both positive and negative effects. Among the disease-associated predicted 156 HLA-B-bound epitopes, Env-derived epitopes alone accounted for 6.4% of variation in 157 spVL, the highest among all HIV-1 proteins (Figure 3A) . In addition to already known 158
Env-derived epitopes associated with disease control e.g. RIKQIINMW, HRLRDLLLI 22 , 159 ERYLKDQQL 23 , our analysis revealed previously undescribed HLA-epitope complexes Figure 4) . All of these clusters included both novel and 177 previously described epitopes, and three of them were defined by both risk-and 178 protection-conferring alleles. Furthermore, all HLA variants bound peptides of multiple Figure 4) . Overall, the cluster analysis shows that our PepWAS approach 182 identifies groups of peptides with distinct motifs that are different from HLA variant-183 specific binding motifs. 184
Generally, the 24 disease-associated epitopes predicted to be bound by HLA-B*57:01 185 (but also by other alleles), accounted for the highest level of variation in spVL, even 186 though they derived from 5 different HIV-1 proteins (Figure 3B, C and Figure S3 ). One 187 of these epitopes, the well characterized HIV-1 Gag epitope ISPRTLNAW (belonging to 188 the violet cluster in Figure 4) , slightly exceeded the effect of all other epitopes ( Figure  189 3B), in concordance with experimental evidence 24 . Predicted HIV-1 epitopes with a 190 So far, our analysis was based on the HIV-1 genome reference sequence. Though widely 197 used for research, focusing on this sequence accession may restrict our findings. We thus 198 repeated the entire analysis using the HIV-1 proteome consensus sequence from the Los 199
Alamos database, which incorporates major variation across different HIV-1 strains. The 200 results remained qualitatively the same (Figure S5 and Table S6 ). However, HIV is well 201 known to exhibit substantial within-host evolution 26, 27 and it is easily conceivable that 202 the ability of a patient's HLA variants to bind HIV epitopes is significantly affected by 203 genetic variation in the patient's HIV population 17 . We therefore also analyzed patient-204 In 4 out of 8 HIV-1 proteins for which autologous sequences were available, the variation (estimated as adjusted ΔR 2 ) in set point viral load (spVL) associated with individual HLA-bound epitope repertoires increased when we predicted epitopes from autologous sequences instead of the HIV-1 reference sequence. Autologous sequence information was only available for a small subset of patients and coverage of the given protein sequences was incomplete. Estimates for both reference and autologous epitopes are therefore based on the same subset of patients and incomplete sequence data in order to make them comparable. No sequence data was available for the Env protein.
specific autologous HIV-1 sequence information, which was available for a small subset 205 of patients, covering 8 of the 10 HIV-1 proteins ( Table 1) . For 4 proteins (Gag, Pol, Vif 206
and Nef) we found that HLA-bound epitope repertoires predicted from autologous 207 sequences accounted for more variation in spVL than their homologs from the reference 208 sequence ( Table 1) . 209
Overall, our findings reveal a functional basis of the robustly established association 210 between HLA genes and HIV-1 infection outcome. We show that both quantity and 211 quality of HLA-bound HIV epitopes contribute to controlling a patient's viral load. Our 212 data also suggests a more important role for Env protein-derived epitopes than previously 213 thought. Ultimately, our PepWAS approach of combining computational HLA-specific 214 epitope prediction with disease phenotype validation provides a promising avenue for 215 identification and prioritization of novel epitopes as potential targets for immunotherapy. 216
As such it may be applied to any HLA-associated complex disease. Overall, 69 and 37 classical alleles for HLA-B and HLA-A, respectively, were 236 represented in the data ( Figure S1 ). Available measurement of pre-treatment set point 237 viral load (spVL; log10 HIV-1 RNA copies/µl of plasma) was used as quantitative 238 disease phenotype for all patients 4 . All participants were HIV-1-infected adults, and 239 written informed consent for genetic testing was obtained from all individuals as part of 240 the original study in which they were enrolled 4 . 241
242
HLA binding affinity for HIV-1 epitopes: 243
We used the NCBI accession NC_001802.1 as the reference sequence for the HIV-1 244 proteome (M group subtype B). It comprised 10 proteins with sequence length ranging 245 from 82 to 1435 amino acids (Table S7) training data for the prediction methods, which makes the consensus approach more 257 favorable over either of the underlying methods 6 . It also reports the rank of predicted 258 binding affinity of HLA-peptide complexes against predicted affinity of 200,000 random 259 natural peptides. Using this tool, we predicted HLA allele-specific binding affinities for 260 all 9mer peptides generated from the entire HIV-1 proteome. HLA-peptide complexes 261 with predicted binding affinity rank less than 0.5 were retained (corresponding to 262 'strongly bound' peptides 6 ). The breadth of peptides bound by a patient's HLA allele 263 pair was taken as the total number of unique peptides predicted to be bound by both We analyzed autologous HIV-1 sequences from Bartha et al. 16 . Autologous sequences 303
were available for 8 of 10 HIV-1 proteins (only Gp41 segment for Env) but only for a 304 small subset of patients in our cohorts ( Table 1 ). Due to the bulk sequencing of viral 305 RNA from pre-treatment stored plasma with limited coverage, there were large segments 306 of missing sites in individual sequences, further reducing the available sequence 307 information for epitope prediction. For comparison of autologous and reference epitopes, 308
for each individual we extracted the corresponding parts of the reference sequence for 309 spV L = β1 * variable + β2 * covariates + ε1 spV L = β2 * covariates + ε2 which autologous sequence data was available. HLA-B binding affinities were calculated 310 for autologous sequences and homologous reference parts using NetMHCcons-1.1 6 . 311
HLA-peptide complexes with binding affinity rank <0.5 were retained (same criterion as 312 used for the general analysis). The stronger association of autologous epitopes with viral 313 load, compared to reference-based epitopes, further substantiates our epitope prediction 314 pipeline and corroborates that within-host variation of HIV-1 can significantly alter the 315 efficiency of HLA-based immunity. 316 317 HLA-B allele specific escape mutations in HIV-1 epitopes: 318
Of a total of 24 epitopes from the HIV-1 reference sequence that were predicted to be 319 bound by HLA-B*57:01, autologous sequence information was only available for 18. For 320 each of these 18 epitopes, we created a contingency table with the number of patients 321 who are carriers and non-carriers of the HLA-B*57:01 allele, and the number of patients 322 in whom the autologous version of the given epitope is and is not bound by B*57:01. 323
Fischer exact test was performed on the contingency table to calculate the significance. 
